# Phase 2 Purpura, Thrombocytopenic: 30 recruiting (2026)

ClinicalTrials.gov lists 30 trials in phase 2 for Purpura, Thrombocytopenic, Idiopathic that are recruiting or not yet recruiting.

## The full list

Recruiting Phase 2 Purpura, Thrombocytopenic, Idiopathic trials: 30 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/purpura-thrombocytopenic-idiopathic

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 30
- Recruiting or not yet: 30
- Read on: November 19, 2026

## Trials

The 25 newest of 30, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 17, 2026 | NCT07710248 | SG301-SC Injection Safety Study in Subjects With Primary ITP Patients | Hangzhou Sumgen Biotech Co., Ltd. | Phase 2 | Recruiting | Primary Immune Thrombocytopenia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07710248) |
| July 7, 2026 | NCT07687134 | Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Immune Thrombocytopenia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07687134) |
| June 25, 2026 | NCT07669675 | TPO-RA Plus Baricitinib vs. TPO-RA for ITP | Peking University People's Hospital | Phase 2 | Not yet recruiting | ITP - Immune Thrombocytopenia | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07669675) |
| June 22, 2026 | NCT07660172 | A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids. | Novartis Pharmaceuticals | Phase 2 | Not yet recruiting | Primary Immune Thrombocytopenia (ITP) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07660172) |
| February 19, 2026 | NCT07421167 | A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients... | Novartis Pharmaceuticals | Phase 2 | Recruiting | Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES) | 164 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07421167) |
| February 10, 2026 | NCT07400250 | Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have... | Peking Union Medical College Hospital | Phase 2 | Not yet recruiting | Primary Immune Thrombocytopenia (ITP) | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07400250) |
| January 23, 2026 | NCT07362238 | Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | Immune Thrombocytopenia, Treatment | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07362238) |
| January 23, 2026 | NCT07362199 | Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | Immune Thrombocytopenia, Treatment | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07362199) |
| January 2, 2026 | NCT07315373 | Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia | Peking University People's Hospital | Phase 2 | Not yet recruiting | Immune Thrombocytopenia | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07315373) |
| December 22, 2025 | NCT07297563 | Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | Immune Thrombocytopenia, Treatment | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07297563) |
| December 19, 2025 | NCT07294365 | A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11) | Dizal Pharmaceuticals | Phase 2 | Recruiting | Immune Thrombocytopenia (ITP) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07294365) |
| November 18, 2025 | NCT07234019 | Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP) | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | Immune Thrombocytopenia, Treatment | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07234019) |
| August 5, 2025 | NCT07104565 | Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders | Incyte Corporation | Phase 2 | Recruiting | Immune Thrombocytopenia | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07104565) |
| July 31, 2025 | NCT07095127 | Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia | Nuvig Therapeutics, Inc. | Phase 2 | Recruiting | Immune Thrombocytopenia (ITP) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07095127) |
| July 24, 2025 | NCT07083739 | A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in... | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 | Not yet recruiting | Primary Immune Thrombocytopenia | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07083739) |
| July 15, 2025 | NCT07065968 | The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2) | Peking University People's Hospital | Phase 2 | Recruiting | Immune Thrombocytopenia (ITP) | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07065968) |
| July 15, 2025 | NCT07064889 | The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia | Peking University People's Hospital | Phase 2 | Not yet recruiting | Immune Thrombocytopenia | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07064889) |
| July 14, 2025 | NCT07063199 | Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP) | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | Immune Thrombocytopenia, Treatment | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07063199) |
| July 10, 2025 | NCT07057778 | Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP | Peking University People's Hospital | Phase 2 | Not yet recruiting | Immune Thrombocytopenia (ITP) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07057778) |
| June 13, 2025 | NCT07019545 | A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE... | Hellenic Society of Hematology | Phase 2 | Not yet recruiting | Primary Immune Thrombocytopenia (ITP) | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07019545) |
| May 28, 2025 | NCT06992128 | Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A... | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | Primary Immune Thrombocytopenia (ITP) | 129 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06992128) |
| February 21, 2025 | NCT06838962 | Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP) | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | Immune Thrombocytopenia, Treatment | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06838962) |
| January 29, 2025 | NCT06799611 | An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | Immune Thrombocytopenia (ITP), Treatment | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06799611) |
| June 27, 2024 | NCT06478537 | TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination | Peking Union Medical College Hospital | Phase 2 | Recruiting | Immune Thrombocytopenia | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06478537) |
| February 28, 2024 | NCT06281327 | Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | Immune Thrombocytopenia, Treatment | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06281327) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Institute of Hematology & Blood Diseases Hospital, China | 14 |
| Peking University People's Hospital | 5 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 2 |
| Peking Union Medical College Hospital | 2 |
| Hellenic Society of Hematology | 1 |
| [Chia Tai Tianqing Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-co-ltd) | 1 |
| Seoul National University Hospital | 1 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 1 |
| Nuvig Therapeutics, Inc. | 1 |
| [Dizal Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/dizal-pharmaceuticals) | 1 |
| Hangzhou Sumgen Biotech Co., Ltd. | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 22 |
| United States | 3 |
| Greece | 1 |
| South Korea | 1 |
| Australia | 1 |
| France | 1 |
| Italy | 1 |
| Netherlands | 1 |
| Spain | 1 |
| United Kingdom | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hotel supply companies in the United States](https://specstream.ai/data/businesses/hotel-supply-companies/united-states)
- [Ayurveda clinics in the United States](https://specstream.ai/data/businesses/ayurveda-clinics/united-states)
- [Office supply stores in the United States](https://specstream.ai/data/businesses/office-supply-stores/united-states)
- [Construction management firms in the United States](https://specstream.ai/data/businesses/construction-management-firms/united-states)
- [Shipping collection companies in the United States](https://specstream.ai/data/businesses/shipping-collection-companies/united-states)
- [General dentistry practices in the United States](https://specstream.ai/data/businesses/general-dentistry-practices/united-states)
